Authors
Ramzi Dagher, Lauren M Long, Elizabeth J Read, Susan F Leitman, Charles S Carter, Maria Tsokos, Theresa J Goletz, Nilo Avila, Jay A Berzofsky, Lee J Helman, Crystal L Mackall
Publication date
2002/3
Journal
Medical and Pediatric Oncology: The Official Journal of SIOP—International Society of Pediatric Oncology (Societé Internationale d'Oncologie Pédiatrique
Volume
38
Issue
3
Pages
158-164
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Description
Background
Patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma have poor prognoses and limited therapeutic options. We have investigated the use of peptide pulsed vaccination in an attempt to immunologically target the breakpoint region of tumor specific fusion proteins expressed in these tumors.
Procedure
Sixteen patients with recurrent, translocation positive, Ewing sarcoma, and alveolar rhabdomyosarcoma underwent apheresis for collection of peripheral blood mononuclear cells. Following countercurrent centrifugal elutriation, an apheresis product comprised predominantly of monocytes but containing small numbers of circulating immature dendritic cells was pulsed with peptides derived from the breakpoint region of the fusion proteins. Vaccines were administered intravenously concomitant with continuous intravenous rhIL‐2 at 9 × 106 IU/m2/day.
Results
Toxicity was limited to …
Total citations
Scholar articles
R Dagher, LM Long, EJ Read, SF Leitman, CS Carter… - Medical and Pediatric Oncology: The Official Journal of …, 2002